2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. TMPRSS6
  5. TMPRSS6 Inhibitor

TMPRSS6 Inhibitor

TMPRSS6 Inhibitors (7):

Cat. No. Product Name Effect Purity
  • HY-177662
    Sapablursen
    		Inhibitor
    Sapablursen, an antisense oligonucleotide, is designed to reduce the production of TMPRSS6 resulting in increased expression of hepcidin, which is the key regulator of iron homeostasis. Sapablursen can be used in the research of blood diseases such as pol
  • HY-147278C
    Manusiran sodium scrambled negative control
    		Inhibitor
    Manusiran sodium scrambled negative control is the sequence scrambled negative control of Manusiran sodium.
  • HY-177663A
    SARSi-4 sodium scrambled negative control
    		Inhibitor
    SARSi-4 sodium scrambled negative control is the sequence scrambled negative control of SARSi-4 sodium.
  • HY-177662A
    Sapablursen sodium
    		Inhibitor
    Sapablursen sodium, an antisense oligonucleotide, is designed to reduce the production of TMPRSS6 resulting in increased expression of hepcidin, which is the key regulator of iron homeostasis. Sapablursen sodium can be used in the research of blood diseas
  • HY-147278A
    Manusiran sodium
    		Inhibitor
    Manusiran (SLN124) sodium, a GalNAc conjugated 19-mer siRNA targeting TMPRSS6 (transmembrane protease serine 6), reduces plasma iron and increases hepcidin levels[1][2].
  • HY-147278
    Manusiran
    		Inhibitor
    Manusiran (Divesiran) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia.
  • HY-180217
    WGU55
    		Inhibitor
    WGU55 is a selective and potent reversible type II transmembrane serine protease TMPRSS6 inhibitor with a Ki of 12.15 nM. WGU55 inhibits TMPRSS6 activity with an IC50 of 138 nMin KEK293 cells. WGU55 has a Ki of 3510 nM (SI = 289) against the homologous protease matriptase and a Ki of 5.2 μM against the coagulation key protease Factor Xa. WGU55 can be used for the research of iron overload related diseases, such as hereditary hemochromatosis.